ptg-300
Trade name: Rusfertide
Peptideexperimental
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
7
Phase 3
2
Phase 4
0
Earliest trial started Dec 19, 2018 (NCT03802201)
Timeline
Indications
Mechanism of action
- HepcidinANTAGONIST
HAMP antagonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650507 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06033586 | Phase 3 | Dec 1, 2023 | Protagonist Therapeutics |
| NCT05210790 | Phase 3 | Apr 1, 2022 | Protagonist Therapeutics |
| NCT04767802 | Phase 2 | Feb 2, 2021 | Protagonist Therapeutics |
| NCT04516382 | Phase 1 | Sep 14, 2020 | Protagonist Therapeutics |
| NCT04202965 | Phase 2 | Jan 2, 2020 | Protagonist Therapeutics |
| NCT04057040 | Phase 2 | Aug 31, 2019 | Protagonist Therapeutics |
| NCT04054921 | Phase 2 | May 10, 2019 | Protagonist Therapeutics |
| NCT03802201 | Phase 2 | Dec 19, 2018 | Protagonist Therapeutics |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Protagonist Therapeutics | For profit | 8 | 8 | 3 | 2018 |
1 organizations
Page 1 / 1